Acting FDA Commissioner Janet Woodcock Pushes HHS Inspector General to Open Biogen Investigation

Aduhelm’s surprising drug approval continues to make waves throughout the country. In addition to commanding a steep price, a newly revealed relationship between pharmaceutical company Biogen and the Food and Drug Administration (FDA) has attracted interest and criticism. Now, Janet Woodcock, acting FDA commissioner, has joined the many voices calling for an investigation into the relationship.

“The request comes as controversy continues to swirl around the approval, with prominent members of Congress launching probes and Biogen taking the extraordinary step this week to ask for a narrower drug label. Woodcock’s call for a probe also comes less than two weeks after a report from STAT News highlighted a major undertaking from Biogen to get Aduhelm approved that began as early as 2019.” Read more here.

(Source: Max Gelman, Endpoints News, 7/9/21)